The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Abstract
Multiple avenues of research including epidemiology, molecular genetics and cell biology have identified links between Parkinson's disease and type 2 diabetes mellitus. Several recent discoveries have highlighted common cellular pathways that potentially relate neurodegenerative processes with abnormal mitochondrial function and abnormal glucose metabolism. This includes converging evidence identifying that peroxisome proliferator activated receptor gamma coactivator 1-α, a key regulator of enzymes involved in mitochondrial respiration and insulin resistance, is potentially pivotal in the pathogenesis of neurodegeneration in Parkinson's disease. This evidence supports further study of these pathways, most importantly to identify neuroprotective agents for Parkinson's disease, and/or establish more effective prevention or treatment for type 2 diabetes mellitus. In parallel with these advances, there are already randomized trials evaluating several established treatments for insulin resistance (pioglitazone and exenatide) as possible disease modifying drugs in Parkinson's disease, with only preliminary insights regarding their mechanisms of action in neurodegeneration, which may be effective in both disease processes through an action on mitochondrial function. Furthermore, parallels are also emerging between these same pathways and neurodegeneration associated with Alzheimer's disease and Huntington's disease. Our aim is to highlight this converging evidence and stimulate further hypothesis-testing studies specifically with reference to the potential development of novel neuroprotective agents in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 2×
“Survey data reveal that diabetes is established in 8–30% of patients with Parkinson’s disease, consistently in excess of the prevalence found in non-Parkinson’s disease individuals (Chalmanov and Vurbanova, 1987; Pressley et al., 2003).”
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1032913100 · Cited by 1,952
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e745 · Cited by 1,883
Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.956 · Cited by 1,859
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease
Finck, B. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27794 · Cited by 1,432
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Neural mechanisms of ageing and cognitive decline
Bishop, N. A., Lu, T., & Yankner, B. A. (2010) · Nature · doi:10.1038/nature08983 · Cited by 1,323
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 2×
“Exenatide is a synthetic agonist for the GLP-1 receptor and has been granted a license for the treatment of type 2 diabetes with confirmed beneficial effects on glucose control, thought to be mediated by b-cell proliferation, increased insulin production, decreased gluconeogenesis and weight loss that follows chronic…”
BackgroundThe role of exercise and PGC1α in inflammation and chronic disease
Handschin, C., & Spiegelman, B. M. (2008) · Nature · doi:10.1038/nature07206 · Cited by 1,083
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081
Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., & Anandatheerthavarada, H. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710012200 · Cited by 1,080
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy
Chan, N. C., Salazar, A. M., Pham, A. H., Sweredoski, M. J., Kolawa, N. J., Graham, R. L. J., Hess, S., & Chan, D. C. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr048 · Cited by 993
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., & Khrapko, K. (2006) · Nature Genetics · doi:10.1038/ng1778 · Cited by 887
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang-James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 857
Wang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y., Casadesus, G., & Zhu, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804871105 · Cited by 835
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Autophagy gone awry in neurodegenerative diseases
Wong, E., & Cuervo, A. M. (2010) · Nature Neuroscience · doi:10.1038/nn.2575 · Cited by 815
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 753
Keeney, P. M., Xie, J., Capaldi, R. A., & Bennett, J. P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0984-06.2006 · Cited by 747
Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K., Egan, J. M., & Mattson, M. P. (2008) · Nature Neuroscience · doi:10.1038/nn2055 · Cited by 611
Non-CpG methylation of the PGC-1α promoter through DNMT3B controls mitochondrial density.
Barrès, R., Osler, M. E., Yan, J., Rune, A., Fritz, T., Caidahl, K., Krook, A., & Zierath, J. R. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.07.011 · Cited by 602
Cognitive impairment following high fat diet consumption is associated with brain inflammation
Pistell, P. J., Morrison, C. D., Gupta, S., Knight, A. G., Keller, J. N., Ingram, D. K., & Bruce-Keller, A. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.11.010 · Cited by 596
Kapogiannis, D., & Mattson, M. P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70277-5 · Cited by 594
Relation of diabetes to mild cognitive impairment
Luchsinger, J. A., Reitz, C., Patel, B., Tang, M.-X., Manly, J. J., & Mayeux, R. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.570 · Cited by 592
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., Kurinami, H., Shinohara, M., Rakugi, H., & Morishita, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000645107 · Cited by 505
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Chinta, S. J., Mallajosyula, J. K., Rane, A., & Andersen, J. K. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.061 · Cited by 449
N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking
Orr, A. L., Li, S., Wang, C.-E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P. G., Greenamyre, J. T., & Li, X.-J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0106-08.2008 · Cited by 430
Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S.-W., Marupudi, N. I., Torp, R., Torgner, I. A., Ottersen, O. P., Dawson, T. M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi211 · Cited by 421
Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405
UNGER, J., LIVINGSTON, J., & MOSS, A. (1991) · Progress in Neurobiology · doi:10.1016/0301-0082(91)90015-s · Cited by 404
Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J., & Schulz, J. B. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 382
Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics
Irrcher, I., Aleyasin, H., Seifert, E. L., Hewitt, S. J., Chhabra, S., Phillips, M., Lutz, A. K., Rousseaux, M. W. C., Bevilacqua, L., Jahani-Asl, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq288 · Cited by 382
PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia
Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D., & Pasinetti, G. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.588 · Cited by 378
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 373
Yokota, T., Sugawara, K., Ito, K., Takahashi, R., Ariga, H., & Mizusawa, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.056 · Cited by 356
Neurodegenerative disorders associated with diabetes mellitus
Ristow, M. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0552-1 · Cited by 352
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., & Mathews, W. R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00424.2003 · Cited by 338
Cooper, J. M., Mann, V. M., & Schapira, A. H. V. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90270-u · Cited by 335
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322
Tuomilehto, J., Rastenytė, D., Jousilahti, P., Sarti, C., & Vartiainen, E. (1996) · Stroke · doi:10.1161/01.str.27.2.210 · Cited by 322
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
Perier, C., Tieu, K., Guégan, C., Caspersen, C., Jackson-Lewis, V., Carelli, V., Martinuzzi, A., Hirano, M., Przedborski, S., & Vila, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508215102 · Cited by 308
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Gerlach, M., Riederer, P., Przuntek, H., & Youdim, M. B. H. (1991) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(91)90073-q · Cited by 307
The insulin paradox: aging, proteotoxicity and neurodegeneration
Cohen, E., & Dillin, A. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2474 · Cited by 303
MitoNEET is a uniquely folded 2Fe–2S outer mitochondrial membrane protein stabilized by pioglitazone
Paddock, M. L., Wiley, S. E., Axelrod, H. L., Cohen, A. E., Roy, M., Abresch, E. C., Capraro, D., Murphy, A. N., Nechushtai, R., Dixon, J. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707189104 · Cited by 302
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300
Ek, J., Andersen, G., Urhammer, S. A., Gæde, P. H., Drivsholm, T., Borch-Johnsen, K., Hansen, T., & Pedersen, O. (2001) · Diabetologia · doi:10.1007/s001250100032 · Cited by 293
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263
Complex I, iron, and ferritin in Parkinson's disease substantia nigra
Mann, V. M., Cooper, J. M., Daniel, S. E., Srai, K., Jenner, P., Marsden, C. D., & Schapira, A. H. V. (1994) · Annals of Neurology · doi:10.1002/ana.410360612 · Cited by 251
The Relationship Between Diabetes Mellitus and Parkinson'S Disease
Sandyk, R. (1993) · International Journal of Neuroscience · doi:10.3109/00207459309003322 · Cited by 243
Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations
Müftüoglu, M., Elibol, B., Dalmızrak, Ö., Ercan, A., Kulaksız, G., Ögüs, H., Dalkara, T., & Özer, N. (2004) · Movement Disorders · doi:10.1002/mds.10695 · Cited by 237
The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism
Pressley, J. C., Louis, E. D., Tang, M.-X., Cote, L., Cohen, P. D., Glied, S., & Mayeux, R. (2003) · Neurology · doi:10.1212/wnl.60.1.87 · Cited by 229
Hara, K., Tobe, K., Okada, T., Kadowaki, H., Akanuma, Y., Ito, C., Kimura, S., & Kadowaki, T. (2002) · Diabetologia · doi:10.1007/s00125-002-0803-z · Cited by 223
Hu, M. T. M., Taylor-Robinson, S. D., Chaudhuri, K. R., Bell, J. D., Labbe, C., Cunningham, V. J., Koepp, M. J., Hammers, A., Morris, R. G., Turjanski, N., et al. (2000) · Brain · doi:10.1093/brain/123.2.340 · Cited by 221
Mitochondrial diabetes mellitus: a review
Gerbitz, K.-D., van den Ouweland, J. M. W., Maassen, J. A., & Jaksch, M. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00036-4 · Cited by 219
Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes.
Hurlbert, M. S., Zhou, W., Wasmeier, C., Kaddis, F. G., Hutton, J. C., & Freed, C. R. (1999) · Diabetes · doi:10.2337/diabetes.48.3.649 · Cited by 218
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. (2007) · Neurology · doi:10.1212/01.wnl.0000279519.99344.ad · Cited by 213
Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent
Armanini, M. P., Hutchins, C., Stein, B. A., & Sapolsky, R. M. (1990) · Brain Research · doi:10.1016/0006-8993(90)91734-x · Cited by 206
Body mass index and the risk of Parkinson disease
Hu, G., Jousilahti, P., Nissinen, A., Antikainen, R., Kivipelto, M., & Tuomilehto, J. (2006) · Neurology · doi:10.1212/01.wnl.0000247052.18422.e5 · Cited by 203
Summers, S. A., & Nelson, D. H. (2005) · Diabetes · doi:10.2337/diabetes.54.3.591 · Cited by 185
Heilbronn, L. K., Gan, S. K., Turner, N., Campbell, L. V., & Chisholm, D. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2210 · Cited by 184
The Outer Mitochondrial Membrane Protein mitoNEET Contains a Novel Redox-active 2Fe-2S Cluster
Wiley, S. E., Paddock, M. L., Abresch, E. C., Gross, L., van der Geer, P., Nechushtai, R., Murphy, A. N., Jennings, P. A., & Dixon, J. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700107200 · Cited by 179
Proteomics Analysis Identifies Phosphorylation-dependent α-Synuclein Protein Interactions
McFarland, M. A., Ellis, C. E., Markey, S. P., & Nussbaum, R. L. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800116-mcp200 · Cited by 176
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD
Pyle, A., Foltynie, T., Tiangyou, W., Lambert, C., Keers, S. M., Allcock, L. M., Davison, J., Lewis, S. J., Perry, R. H., Barker, R., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20417 · Cited by 176
Self-citationINCREASED FREQUENCY OF DIABETES MELLITUS IN PATIENTS WITH HUNTINGTON'S CHOREA
Podolsky, S., Leopold, N., & Sax, D. (1972) · The Lancet · doi:10.1016/s0140-6736(72)91092-6 · Cited by 172
Fai Poon, H., Frasier, M., Shreve, N., Calabrese, V., Wolozin, B., & Butterfield, D. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.009 · Cited by 165
Obesity, diabetes, and risk of Parkinson's disease
Palacios, N., Gao, X., McCullough, M. L., Jacobs, E. J., Patel, A. V., Mayo, T., Schwarzschild, M. A., & Ascherio, A. (2011) · Movement Disorders · doi:10.1002/mds.23855 · Cited by 164
Midlife adiposity and the future risk of Parkinson’s disease
Abbott, R. D., Ross, G. W., White, L. R., Nelson, J. S., Masaki, K. H., Tanner, C. M., Curb, J. D., Blanchette, P. L., Popper, J. S., & Petrovitch, H. (2002) · Neurology · doi:10.1212/wnl.59.7.1051 · Cited by 163
Wu, W., Brickman, A. M., Luchsinger, J., Ferrazzano, P., Pichiule, P., Yoshita, M., Brown, T., DeCarli, C., Barnes, C. A., Mayeux, R., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21557 · Cited by 162
Mitophagy: the latest problem for Parkinson's disease
Vives-Bauzá, C., & Przedborski, S. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.002 · Cited by 161
Exploring the link between glucocerebrosidase mutations and parkinsonism
Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 160
Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P. L., McGeer, E. G., & Hirayama, K. (1994) · Acta Neuropathologica · doi:10.1007/bf00313602 · Cited by 159
Kim Chung, L. T., Hosaka, T., Yoshida, M., Harada, N., Sakaue, H., Sakai, T., & Nakaya, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.015 · Cited by 158
Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease
Luoma, P. T., Eerola, J., Ahola, S., Hakonen, A. H., Hellström, O., Kivistö, K. T., Tienari, P. J., & Suomalainen, A. (2007) · Neurology · doi:10.1212/01.wnl.0000276955.23735.eb · Cited by 154
Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 154
Saller, C. F., & Chiodo, L. A. (1980) · Science · doi:10.1126/science.6254155 · Cited by 147
Simon, D. K., Pulst, S. M., Sutton, J. P., Browne, S. E., Beal, M. F., & Johns, D. R. (1999) · Neurology · doi:10.1212/wnl.53.8.1787 · Cited by 141
Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Wang, Y., Drucker, D. J., & Koletar, M. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-133454 · Cited by 138
Insulin receptor mRNA in the substantia nigra in Parkinson's disease
Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimurâ, H., Yamamoto, T., & Okada, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12357-0 · Cited by 137
Raković, A., Grünewald, A., Seibler, P., Ramírez, A., Kock, N., Orolicki, S., Lohmann, K., & Klein, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq215 · Cited by 129
Complex I: Inhibitors, inhibition and neurodegeneration
Schapira, A. H. V. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.028 · Cited by 126
Mounier, C., & Posner, B. I. (2006) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y05-152 · Cited by 124
Quinn, L. P., Crook, B., Hows, M. E. P., Vidgeon-Hart, M., Chapman, H., Upton, N., Medhurst, A. D., & Virley, D. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.78 · Cited by 124
Tansey, M. G. (2007) · Frontiers in bioscience · doi:10.2741/2713 · Cited by 120
The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells
Ghosh, S., Patel, N., Rahn, D. A., McAllister, J., Sadeghi, S., Horwitz, G., Berry, D., Wang, K. X., & Swerdlow, R. H. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033845 · Cited by 119
Guo, Z., Ersöz, A., Butterfield, D. A., & Mattson, M. P. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750314.x · Cited by 118
Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.
Bowen, B. C., Block, R. E., Sanchez‐Ramos, J., Pattany, P. M., Lampman, D. A., Murdoch, J. B., & Quencer, R. M. (1995) · PubMed · Cited by 111
A New Alzheimers Disease Interventive Strategy: GLP-1
Perry, T. R., & Greig, N. H. (2004) · Current Drug Targets · doi:10.2174/1389450043345245 · Cited by 110
Running reduces stress and enhances cell genesis in aged mice
Kannangara, T. S., Lucero, M. J., Gil-Mohapel, J., Drapala, R. J., Simpson, J. M., Christie, B. R., & van Praag, H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.025 · Cited by 107
Peroxidase Mechanism of Lipid-dependent Cross-linking of Synuclein with Cytochrome c
Bayır, H., Kapralov, A. A., Jiang, J., Huang, Z., Tyurina, Y. Y., Tyurin, V. A., Zhao, Q., Belikova, N. A., Vlasova, I. I., Maeda, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900418200 · Cited by 102
Parkin expression in the adult mouse brain
Stichel, C. C., Augustin, M. A., Kühn, K., Zhu, X., Engels, P., Ullmer, C., & Lübbert, H. (2000) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2000.01314.x · Cited by 98
Regional comparisons of brain glucose influx
LaManna, J. C., & Harik, S. I. (1985) · Brain Research · doi:10.1016/0006-8993(85)90039-3 · Cited by 86
Oxidized DJ-1 Interacts with the Mitochondrial Protein BCL-XL
Ren, H., Fu, K., Wang, D., Mu, C., & Wang, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.207134 · Cited by 86
Fan, R., Li, X., Gu, X., Chan, J. C. N., & Xu, G. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01238.x · Cited by 84
BOYD, A. E., Lebovitz, H. E., & Feldman, J. M. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-5-829 · Cited by 84
Metabolic Responses to Acute and Chronic l -Dopa Administration in Patients with Parkinsonism
Sirtori, C. R., Bolme, P., & Azarnoff, D. L. (1972) · New England Journal of Medicine · doi:10.1056/nejm197210122871501 · Cited by 82
Mitochondrial function and endocrine diseases
Stark, R., & Roden, M. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01773.x · Cited by 75
Toro, P., Schönknecht, P., & Schröder, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0981 · Cited by 71
Glucose intolerance in parkinson's disease
Lipman, I. J., Boykin, M. E., & Flora, R. E. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90031-9 · Cited by 68
Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa
Woert, M. H. V., & Mueller, P. S. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part2360 · Cited by 66
PROGRESSION AND PROGNOSIS IN PARKINSONʼS DISEASE
Schwab, R. S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196006000-00017 · Cited by 66
Blalock, E. M., Grondin, R., Chen, K.-C., Thibault, O., Thibault, V., Pandya, J. D., Dowling, A. L. S., Zhang, Z., Sullivan, P. G., Porter, N. M., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3956-09.2010 · Cited by 64
Genetic Basis for Resistance to Parathyroid Hormone
Levine, M. A., Germain‐Lee, E. L., & de Beur, S. M. J. (2003) · Hormone Research in Paediatrics · doi:10.1159/000074508 · Cited by 62
Bhat, A., Koul, A., Rai, E., Sharma, S., Dhar, M. K., & Bamezai, R. N. K. (2007) · Human Genetics · doi:10.1007/s00439-007-0352-0 · Cited by 61
Diabetes decreases limbic extracellular dopamine in rats
Murzi, E., Contreras, Q., Teneus, L., Valecillos, B., Parada, M. A., de Parada, M. P., & Hernandez, L. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12232-x · Cited by 51
The effect of diabetes and stroke at baseline and during follow-up on stroke mortality
Hu, G., Jousilahti, P., Sarti, C., Antikaínen, R., & Tuomilehto, J. O. (2006) · Diabetologia · doi:10.1007/s00125-006-0378-1 · Cited by 44
Greggio, E., Bisaglia, M., Civiero, L., & Bubacco, L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-6 · Cited by 43
Mineralocorticoid receptor activation restores medial perforant path LTP in diabetic rats
Stranahan, A. M., Arumugam, T. V., Lee, K. M., & Mattson, M. P. (2010) · Synapse · doi:10.1002/syn.20758 · Cited by 28
Insulin-mediated effects of glucose on dopamine metabolism
Montefusco, O., Assini, M. C., & Missale, C. (1983) · Acta Diabetologica · doi:10.1007/bf02629132 · Cited by 27
Staiger, H., Stefan, N., Machicao, F. E., Fritsche, A., & Häring, H. (2005) · Diabetologia · doi:10.1007/s00125-005-0061-y · Cited by 23
[Clinical experience with tolbutamide in Parkinson's disease].
Barbeau, A., GIGUERE, R., & Hardy, J. (1961) · PubMed · Cited by 17
Hara, K., Yamamoto, K., Anegawa, T., Sakuta, R., & Nakamura, M. (1994) · PubMed · Cited by 15
A Feedforward Loop Links Gaucher and Parkinson's Diseases?
Cookson, M. (2011) · Cell · doi:10.1016/j.cell.2011.06.031 · Cited by 11
[Diabetes mellitus in parkinsonism patients].
Chalmanov, V., & Vŭrbanova, M. (1987) · PubMed · Cited by 9
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationSchapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Self-citation
Metadata
- Authors
- Aviles-Olmos, I., Limousin, P., Lees, A., & Foltynie, T.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-17
- Volume
- 136
- Issue
- 2
- Pages
- 374-384
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2127558621
- Cited by
- 283
- References
- 146
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.